lutetium has been researched along with Renal Insufficiency in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Argiroffi, G; Baccini, M; Centonze, G; Fuoco, V; Garanzini, EM; Gherardini, L; Kirienko, M; Maccauro, M; Milione, M; Prinzi, N; Pusceddu, S; Scalorbi, F; Seregni, E | 1 |
| Bilha, SC; Constantin, V; Covic, A; Matovic, M; Nistor, I; Simona, V; Stefanescu, C; Stolniceanu, CR | 1 |
1 review(s) available for lutetium and Renal Insufficiency
| Article | Year |
|---|---|
Nephrotoxicity/renal failure after therapy with 90Yttrium- and 177Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: a systematic review.
Topics: Humans; Isotope Labeling; Kidney; Lutetium; Neuroendocrine Tumors; Radioisotopes; Renal Insufficiency; Somatostatin; Yttrium Radioisotopes | 2020 |
1 other study(ies) available for lutetium and Renal Insufficiency
| Article | Year |
|---|---|
Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT.
Topics: Aged; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lutetium; Male; Middle Aged; Models, Theoretical; Neoplasm Grading; Neoplasm Staging; Neuroendocrine Tumors; Prognosis; Radioisotopes; Radiopharmaceuticals; Renal Insufficiency | 2021 |